Colforsin (Forskolin)

For research use only. Not for use in humans.

製品コードS2449 別名:Coleonol

Colforsin (Forskolin)化学構造

CAS No. 66575-29-9

Colforsin (Forskolin, Coleonol) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.

サイズ 価格(税別) 在庫  
JPY 20200 あり
JPY 46800 あり
JPY 63400 あり
JPY 96600 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(74)

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Colforsin (Forskolin, Coleonol) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29  M1fzXGFxd3C2b4Ppd{BCe3OjeR?= MoCzOFDDqM7:TR?= NYHDPHdUPDkEoHi= NGjXPXRFVVOR MnfUbY5lfWOnczDjbIFv\2W|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?= MmP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 M3;Zb2Fxd3C2b4Ppd{BCe3OjeR?= NIXi[YU1OMLizszN NVfiWWNkPDkEoHi= MYXEUXNQ MV3pcoR2[2W|IHPoZY5o\XNiaX6geIhmKHCqb4PwbI9zgWyjdHnvckB{fGG2dYOgc4YhWFB{QTD0ZZJo\XS| MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
HT-29  Mn2yRZBweHSxc3nzJGF{e2G7 Mn3aOFDDqM7:TR?= MlfzOFjDqGh? MorCSG1UVw>? NVzzSVExcW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 NXPycI5jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
SW480 MlmxRZBweHSxc3nzJGF{e2G7 NEjXRYw1OMLizszN M3TnfVQ5yqCq NVfsbXNsTE2VTx?= MVnpcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= NGDLTmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
HT-29  NIHuZ2tHfW6ldHnvckBCe3OjeR?= M3HYd|QxyqEQvF2= NGT6PYc4KGR? NHPoTJZFVVOR M334UpJm\HWlZYOgZ49td26xc4Do[ZJmKG[xcn3heIlwdiClYYDhZoltcXS7wrC= NGDzcpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
SW480 MUjGeY5kfGmxbjDBd5NigQ>? NWmzd4g6PDEEoN88US=> Moe2O{Bl NWPmSXJHTE2VTx?= MoKwdoVlfWOnczDjc4xwdm:|cHjldoUh\m:{bXH0bY9vKGOjcHHibYxqfHoEoB?= NIXrW2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
HT-29  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH75OlE1OMLizszN NWXlTZBIOC15MjDo NEHqZ29FVVOR MlvwbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> M1fnUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
SW480 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq4cmk1OMLizszN Mm\SNE04OiCq MonsSG1UVw>? NX;4UZVIcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? M4\2XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
HT-29  MVjGeY5kfGmxbjDBd5NigQ>? M{\FblQxyqEQvF2= NXHOVWptPDkEoHi= MkPBSG1UVw>? NVXwfopE[WO2aY\heIV{KFCSMlG= NVHuOZVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
SW480 Ml\uSpVv[3Srb36gRZN{[Xl? M2ixVlQxyqEQvF2= MYe0POKhcA>? NHnJXXJFVVOR Mn;xZYN1cX[jdHXzJHBROkF? NVT0PI1HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
C6 M2jCRmZ2dmO2aX;uJGF{e2G7 NHKyNVEyOCEQvF5CpC=> NV7FOHl3OjBibXnu MmLCbY5kemWjc3XzJINCVVBiYXPjeY12dGG2aX;u MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OUSxO{c,OjVyNkm0NVc9N2F-
Huh-7 M4\5b2Z2dmO2aX;uJGF{e2G7 MWWwMVIxKM7:TR?= MkThNkBpyqB? M3qwNJJme3WudIOgbY4h[SCmb4PlMYRmeGWwZHXueEBqdmO{ZXHz[UBqdiClLV35Z{BmgHC{ZYPzbY9vKGG2IITo[UBxem:2ZXnuJIFv\CCvUl7BJIxmfmWucx?= NEC3PZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVg{PCd-MkWxNFk5OzR:L3G+
THP-1  M2fabWZ2dmO2aX;uJGF{e2G7 M4HuUlEwOTBizszN Ml7WNuKhcA>? NHXPTI1FVVORwrC= NEHjNHR{fXCycnXzd4V{KE2FUD2xJJBzd2S3Y4Tpc47DqA>? NXPYNWZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVQ5QDJpPkK1NVU1QDh{PD;hQi=>
BeWo  Ml34SpVv[3Srb36gRZN{[Xl? MkDjNlAhyrWP NVrvZ|NbPDhiaB?= NF3HUYNFVVORwrC= M{KyWYlv\HWlZYOgZ4VtdCCodYPpc44> Ml\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzOES0O|coRjJ3MUi0OFc4RC:jPh?=
ventricular cardiomyocytes  MlLYSpVv[3Srb36gRZN{[Xl? NH;Y[mwxNjBzLUGwJO69VQ>? M4nZTIV3d2unczDhckBqdm:2cn;wbYMhemW|cH;ud4UhOTJywsGxOUUh[WKxdnWgZoF{[Wxid3n0bEBidiCHQ{WwxsBw\iB{LkKgxtVO MkPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEOxNVMoRjJ3MkCzNVE{RC:jPh?=
ventricular cardiomyocytes  NH\MV4hHfW6ldHnvckBCe3OjeR?= NUHrfFQ5OC5yMT2xNEDPxE1? NH6zSmNqdmO{ZXHz[ZMhKGODTWCgZYNkfW23bHH0bY9v NVexVFI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFMyOTNpPkK1NlA{OTF|PD;hQi=>
MIN6  NEeyOHNHfW6ldHnvckBCe3OjeR?= M2[yTVExKM7:TdMg MXuzJIg> MVHpcoNz\WG|ZYOgSFMhdVKQQTDlfJBz\XO|aX;u NV;VenhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFEyOjRpPkK1NlQyOTJ2PD;hQi=>
L6 M{fvbmZ2dmO2aX;uJGF{e2G7 MVe0NEDDvU1? NITC[IUzPCCq MmHTbY5pcWKrdIOgSG1JOS2rbnT1Z4VlKEGtdDDhZ5RqfmG2aX;u MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ2N{W1NEc,OjV{NEe1OVA9N2F-
HEK‐CFTR NVrjO257TnWwY4Tpc44hSXO|YYm= NUjUWnRvOuLCk{WwxsDPxE1? M3fVOVAuOTJibXnu MX3EUXNQyqB? M4m0T4lv\HWlZYOgZUBld3On4pEQ[IVx\W6mZX70JIlw\GmmZTDl[oZtfXkEoB?= NFS1clE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|IxPyd-MkWyOlMzODd:L3G+
SK-N-SH MoHPR4VtdCCYaXHibYxqfHliQYPzZZk> NGLZV2MyOCEQvF5CpC=> NUX3Z|c3PDhiaB?= MkXN[Y5p[W6lZYOgV2suVi2VSDDu[ZVzd2KuYYP0c41iKGOnbHygeoli[mmuaYT5 NXHNbYUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlYxPjNpPkK1NlY3ODZ|PD;hQi=>
SK-N-AS  MkjNSpVv[3Srb36gRZN{[Xl? NUDsVnBIOTBizszNxsA> MWmxNE8{OC94MDDtbY4> M3[2VIlv[3KnYYPld{Bt\X[nbIOgc4YheC4Qsj3jZZRmdmmwIDjz[ZI3PzVrIHHu[EBqdmS3Y3XzJIFk[3WvdXzheIlwdiCxZjDwMe6zNWOjdHXubY4hMHOnck[3OUkhcW5iKIDldokqdnWlbHXhdkBz\Werb37z MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  M2rKPGZ2dmO2aX;uJGF{e2G7 NHnnPJgyOCEQvF5CpC=> M3zXcVMxKG2rbh?= NHewbm9qdmS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kDPui2lYYTlcolvKCi|ZYK2O|UqNCCyLVfTT|PPuiBqc3XyPUkh[W6mIHPvcoNwdWm2YX70JIhq\2incjDs[ZZmdHNib3[gZYN1cX[nLDD1cpBpd3OyaH;yfYxifGWmLDFOtk1k[XSnbnnu M2jqd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[2NFY{Lz5{NUK2OlA3OzxxYU6=
SK-N-AS  M{jWW2Z2dmO2aX;uJGF{e2G7 NVXLTlM1OTBizszNxsA> MnrlNlQhcA>? MlX6bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIN6[2yrbjDENS=> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  NXLobWpFTnWwY4Tpc44hSXO|YYm= M3TFe|ExKM7:TdMg NIC0WXYzPCCq NVTJNHFZcW6lcnXhd4V{KHSqZTDjRW1RKGyndnXsd:Kh NFHGSnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2OlA3Oyd-MkWyOlYxPjN:L3G+
SK-N-AS  MkS0R4VtdCCYaXHibYxqfHliQYPzZZk> Ml21NVAh|ryPwrC= NILnTIQzPC92ODDo NFPlOVNmdmijbnPld{B1cW2nLXTldIVv\GWwdHz5JINmdGy3bHHyJJZq[WKrbHn0feKh NE\Hb|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2OlA3Oyd-MkWyOlYxPjN:L3G+
granulosa cells MXrGeY5kfGmxbjDBd5NigQ>? NV[3fI5vOTBizszN M3XvPVI1KGh? MlLPbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiUlfTNkBxem:vb4TldkBi[3Srdnn0fS=> M3PqdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O5NVA2Lz5{NUOzPVExPTxxYU6=
granulosa cells NIHVR41HfW6ldHnvckBCe3OjeR?= MV[xNEDPxE1? NU\t[nk5OjRiaB?= NF3KPWZqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kBFVkFxcILveIVqdiClb33wcIV5 NGjvZm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzPVExPSd-MkWzN|kyODV:L3G+
granulosa cells M3S1SWZ2dmO2aX;uJGF{e2G7 NHrNWlEyOCEQvF2= NIHJeG4yOi9{NDDo M1myeolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIILldI9zfGW{IHHjeIl3cXS7IH\vdkB1cGVibH;u[4V{fCCocnHncYVvfCBq4pkSPFU1NytzOGLHV|IvVFWFKR?= NXPlc5BsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|kyODVpPkK1N|M6OTB3PD;hQi=>
granulosa cells M1S1UGZ2dmO2aX;uJGF{e2G7 Mn:wNVAh|ryP M1vaOlEzNzJ2IHi= Mm\TbY5kemWjc3XzJJRp\SCuZY\lcJMhd2cEoGLHV|LDqG2UTlG= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN|OUGwOUc,OjV|M{mxNFU9N2F-
BeWo  MmjOSpVv[3Srb36gRZN{[Xl? MmS2NlDDqML3TR?= NYPT[VRPPDkEoHlCpC=> NXTiVmNoTE2VT9Mg MWrkc5dvemWpdXzheIV{KHSqZTDs[ZZmdCCxZjDHR20uOQ>? MnjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|NkKyOlAoRjJ3M{[yNlYxRC:jPh?=
BeWo  NYPMU3Q{TnWwY4Tpc44hSXO|YYm= M1G1O|IxyqEEtV2= MnXsOFjDqGkEoB?= M1\mN2ROW00EoB?= Mlvj[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wxib3[gWG1GVUZzNh?= NGPFPHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NlI3OCd-MkWzOlIzPjB:L3G+
BeWo  NUDpPYs6TnWwY4Tpc44hSXO|YYm= NUG1cmExOjEEoNM1US=> NWiw[nFpPDkEoHlCpC=> MmXPSG1UV8Li MkXkbY5kemWjc3XzJJRp\SCkZYThMYhETyC{ZXzlZZNm NHfQdZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NlI3OCd-MkWzOlIzPjB:L3G+
EM1  MXTGeY5kfGmxbjDBd5NigQ>? M17UNVE26oDMzszN M{nIe|Q5KGh? MoPOdoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZtMgUGlHyqCxctMgVHRIWzMEoHnuxsBESUyULTDvduKhTVCDQ{Ktd4lt\W6lZXSgSW0yKGOnbHzzxsA> NX3BcG9lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzO|g3PjFpPkK1N|c5PjZzPD;hQi=>
Primary bovine chondrocytes MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS4PI42|ryP MYC0PEBp NULydGxsemW4ZYLz[ZMhfGinIHnubIljcXSxcomg[YZn\WO2IH;mJINmdGWlb4jpZkBwdiCycn;sbYZmemG2aX;uJIlvKGe{b4f0bEBxdGG2ZTDjbI9v\HKxY4n0[ZM> NXzUXIZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NFYxOTZpPkK1OFA3ODF4PD;hQi=>
RBMECs M3f3bWZ2dmO2aX;uJGF{e2G7 NEHDXJI2yqEQvF2= M2fCPFEhcA>? NGfNNnhjdG:la4OgeIhmKGGldHnuJIN6fG:|a3Xs[ZRwdiC{ZXHydoFv\2WvZX70JJNm\W5id3n0bEBGVUGSLVnJJJRz\WG2bXXueOKh M1rwXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs Moi0SpVv[3Srb36gRZN{[Xl? NYK3UXJbPcLizszN NEDZboQyKGh? MVPicI9kc3NidHjlJGVOSVBvSVmtbY5lfWOnZDDjbIFv\2ViaX6gUWxEKHCqb4PwbI9zgWyjdHnvci=> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs MWXGeY5kfGmxbjDBd5NigQ>? Mn76OeKh|ryP MnPENUBp MYPy[ZZmenOnczD0bIUh[2ijbnfld{BqdiCcTz2xJIRqe3S{aXL1eIlwdiC|ZXXuJJdqfGhiRV3BVE1KUSC2cnXheI1mdnR? NFrFbG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxOlY2OSd-MkW0NVY3PTF:L3G+
RBMECs NVjVZYFKTnWwY4Tpc44hSXO|YYm= M4LtWFXDqM7:TR?= NFTrOmYyKGh? MnfRbY5pcWKrdIOgeIhmKGSnY4LlZZNm\CCxZjDhcY92dnRib3[gXm8uOSCrbjDNSpMhcW6mdXPl[EBjgSCHTVHQMWlK NEnQNI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxOlY2OSd-MkW0NVY3PTF:L3G+
RBMECs NX;3bIdETnWwY4Tpc44hSXO|YYm= MWK1xsDPxE1? M33rUFEhcA>? NVH3XpNHeHKndnXueJMhfGinIHnuZ5Jm[XOnIHnuJGhTWCCobIX4JIFkem:|czD0bIUhSlSEIHnu[JVk\WRiYomgJGVOSVBvSVm= M3nuSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs MkTCSpVv[3Srb36gRZN{[Xl? M1u0XlXDqM7:TR?= NYrBUmxHOSCq MWHwdoV3\W62czD0bIUhTU2DUD3JTU1qdmS3Y3XkJHRGTVJidnHseYUh\GWlcnXhd4U> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs NGLsfnRHfW6ldHnvckBCe3OjeR?= NYrpTIV4PcLizszN M3X0TlEhcA>? M4HKUYJtd2OtczD0bIUh[WO2aY\heIlwdiCxZjDSbI9CN1KRQ1ugbY5lfWOnZDDifUBGVUGSLVnJ NYDDUYw6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs M4f3V2Z2dmO2aX;uJGF{e2G7 MnrCNE4xPS9yLkWvOUDPxE1? MoHMNE4zPSCq NIntcJVqdmO{ZXHz[ZMh[0GPUDDjc45k\W62cnH0bY9v MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
ThGCs  NIrZSnZHfW6ldHnvckBCe3OjeR?= NELOfHYyOOLCit88US=> MnvpN{Bp MmPhbY5pcWKrdIOgeIhmKGWoZnXjeEBw\iCKMl:yJI9vKEWGTkKgcXJPSQ>? M1vZU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEOzNFI4Lz5{NUSzN|AzPzxxYU6=
ThGCs  M1T2NWZ2dmO2aX;uJGF{e2G7 NYO3THc{OTEkgJtOwG0> M3fMOlTjiIqq M3;HXYlv[3KnYYPld{BEd0OuMj3pcoR2[2WmIFXEUlLDqGenbnWg[ZhxemW|c3nvci=> NV\ldYw6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|MxOjdpPkK1OFM{ODJ5PD;hQi=>
ThGCs  M174fWZ2dmO2aX;uJGF{e2G7 NY\Q[o86OTEkgJtOwG0> MoLsOQKBkmh? NYHzZ4hU[XWpbXXueJMhUEmIMVGgcIV3\Wy|IIToZZQhf2W{ZTDzeIlufWyjdHXkJIJ6KEOxQ3yy M1vWb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEOzNFI4Lz5{NUSzN|AzPzxxYU6=
LNCaP  NVTiW3RUTnWwY4Tpc44hSXO|YYm= M3Xwd|ExyqEQvF2= NWThNW9WOTJiaNMg M{\1UmROW09? MWXpcoR2[2W|IHGg[JJidWG2aXOgbY5kemWjc3Wgc4YhS1KHQkGgZYN1cX[rdIm= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV2OEC5PUc,OjV3NEiwPVk9N2F-
BeWo MkXCSpVv[3Srb36gRZN{[Xl? Mlv5NlDDqML3TR?= NEGzZ2w1QMLiaB?= M17JNmROW09? M2jvXolv[3KnYYPld{B1cGViYXTo[ZNqd25ib3[gWGhRNTFibX;uc4N6fGW| NVzVdZFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlY4PDBpPkK1OVY3PzRyPD;hQi=>
BeWo M1\VWGZ2dmO2aX;uJGF{e2G7 MmDuNlDDqML3TR?= MXK0POKhcA>? Mln2SG1UVw>? NV3QVWF7cW6lcnXhd4V{KHSqZTDkbYZn\XKnboTpZZRqd25ib3[gRoVYdyClZXzsdy=> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4Nke0NEc,OjV3Nk[3OFA9N2F-
OCI-Ly18  NU\kfmE5TnWwY4Tpc44hSXO|YYm= M2nCUFQxyqEQvF2= MV2xxsBpyqB? M4XocmROW09? MnftbY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= NWTsSYNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O|YzOjBpPkK1OVc3OjJyPD;hQi=>
OCI-Ly1  MofNSpVv[3Srb36gRZN{[Xl? M3XWZlQxyqEQvF2= M{HDOFHDqGkEoB?= NEnjSYNFVVOR M{LTXolv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z MojhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3N{[yNlAoRjJ3NUe2NlIxRC:jPh?=
3T3-L1 Mn7pSpVv[3Srb36gRZN{[Xl? NWnUfYt[Oi53L{Wg{txO Ml\LNlQhcMLi MUDzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCDVFfMJJBzd3SnaX6g[ZhxemW|c3nvckBifCCjbHyg[I9{\XNidHXzeIVl Ml3jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUC1PVcoRjJ3NUmwOVk4RC:jPh?=
HEK293  MV;GeY5kfGmxbjDBd5NigQ>? MkPJOgKBkcL3TR?= M{LYU|MxKG2rbh?= MX7pcoNz\WG|ZYOgZ2FOWCCuZY\lcJM> NIK5TIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5NVkxQCd-MkW1PVE6ODh:L3G+
hADSCs NIja[WFHfW6ldHnvckBCe3OjeR?= M2HWSVXjiIoEtV2= NVrtRo5ROzBibXnu MYLpcoNz\WG|ZYOgZ2FOWCCuZY\lcJM> MmfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUG5NFgoRjJ3NUmxPVA5RC:jPh?=
SH-SY5Y  NYjGfXNKTnWwY4Tpc44hSXO|YYm= MkPHNVDDqM7:TR?= M1T5O|HDqGkEoB?= NFnMfXpqdmO{ZXHz[ZMhSUeFMTDtVm5CKGyndnXs NXL5cHc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVc1OzNpPkK1OVk4PDN|PD;hQi=>
SH-SY5Y  NFLreoNHfW6ldHnvckBCe3OjeR?= NFT0d3MyOMLizszN NHe4XogyyqCqwrC= M3K2Xolv[3KnYYPld{BNXUNiYXP0bZZqfHl? NYHsd3pPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVc1OzNpPkK1OVk4PDN|PD;hQi=>
UACC-647  MYDGeY5kfGmxbjDBd5NigQ>? M1Xjc|ExyqEQvF2= MnPjNVUhdWmw MnvzSG1UVw>? NWXOcYZRcW6lcnXhd4V{KGWHRkKgdIhwe3Cqb4L5cIF1cW:wIHzleoVte8Li NVvMNJZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFMxOjVpPkK1O|A{ODJ3PD;hQi=>
UACC-647  M3Hs[2Z2dmO2aX;uJGF{e2G7 M{fRNlExyqEQvF2= NICwOZYyPSCvaX6= NWLRS|F2TE2VTx?= MkXNbY5pcWKrdIOgSXJMKHCqb4PwbI9zgWyjdHnvci=> MkXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEOwNlUoRjJ3N{CzNFI2RC:jPh?=
UACC-647  NH3nTldHfW6ldHnvckBCe3OjeR?= NITsWWhFVVOR NWfHfol1dGWjZIOgeI8h[SC{aYPlJIlvKGODTWCgcIV3\Wy|IDjFR|UxyqB;wrCyNE4{QcLizszNLS=> NVe2XmJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFMxOjVpPkK1O|A{ODJ3PD;hQi=>
SC MorTSpVv[3Srb36gRZN{[Xl? MV6wMlUh|ryP M3XCelczKGh? NY\lT3hFcW6lcnXhd4V{KGKxdHigT5JwgC1{MDDhcoQhVzFiZYjwdoV{e2mxbjDpckBigG:wLYLlcIF1\WRiU1PzJIJ2fCCxbnz5JGtzd3hvMkFCpC=> NUf5VlFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFU5PzRpPkK1O|A2QDd2PD;hQi=>
SC NGTHSGpHfW6ldHnvckBCe3OjeR?= MXmwMlUh|ryP MlvZNlQhcA>? M33FV41qdWmla4OgeIhmKGWoZnXjeEBw\iClQV3QJIFv[WyxZ4Ogc44hVzFiYX7kJG1DWCCneIDy[ZN{cW:w NGPBVZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewOVg4PCd-MkW3NFU5PzR:L3G+
oocytes MWXGeY5kfGmxbjDBd5NigQ>? MV61JO69VQ>? NWTBXYJHOjRiaB?= MnHpZZR1\W63YYTld{BzcC2rboP1cIlvKGGldHnvckBwdiCxb3P5eIUhT1[ERDDzbYdvcW[rY3HueIx6yqB? NX3R[oVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFc5PTRpPkK1O|A4QDV2PD;hQi=>
BeWo NUTE[FJXTnWwY4Tpc44hSXO|YYm= MYGxNQKBks7:TdMg NUfWbll3PzJiaB?= MorLSG1UVw>? M4n1eo1m\GmjdHXzJGJmX29iY3XscEBlcW[oZYLlcpRq[XSrb36= NXHQOJk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVM1OjVpPkK1O|E{PDJ3PD;hQi=>
GH3 NEmxRo5HfW6ldHnvckBCe3OjeR?= NInUe5MyyqEQvF2= NXHscoFuPi2q NIjw[3hqdmS3Y3XzJHBTVCCjbnSgRo1idDFuIHL1eEBvd3RiQ3zvZ4stKG2UTlGg[ZhxemW|c3nvci=> NIXXPWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO|AyQCd-MkW3NlcxOTh:L3G+
GH3 NIjyc|FHfW6ldHnvckBCe3OjeR?= MlfSNeKh|ryP NVLBNHNqPi2q Mnf6ZZR1\W63YYTld{B1cGViY3;ydoVt[XSrb36gZoV1f2WnbjDQVmwh[W6mIFLtZYwyKGW6cILld5Nqd25? NYryepFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlcxOThpPkK1O|I4ODF6PD;hQi=>
PC12 MVLGeY5kfGmxbjDBd5NigQ>? MkjDNlXDqM7:TR?= MUm0PEBp Ml[0ZYN1cX[jdHXzJINCVVB? MnXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkmzNFUoRjJ3N{[5N|A2RC:jPh?=
BAECs MlfKSpVv[3Srb36gRZN{[Xl? MYiyOUDPxE1? MUWyOEBp MXzlcohidmOnczD0bIUh[WO2aY\heIlwdiCxZjDQVGFT|rFiYomgOUDPxE1icnXzeoVz[XS{b3ysJHQ1UFNuIH;yJFQuWEGS M1zlbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{m4PFI3Lz5{NUe5PFgzPjxxYU6=
GLUTag  NYfm[4NuTnWwY4Tpc44hSXO|YYm= M{j2TlEx6oDLwsXN NE\XVJM1KGh? NEjuRWtqdmO{ZXHz[ZMhfGinIIDDVmVDKGyndnXsd{B4cXSqIITo[UBKSk2[ MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh|Mk[zNUc,OjV6M{K2N|E9N2F-
GLUTag  MmmzSpVv[3Srb36gRZN{[Xl? NV;WbYU{OTEkgJpCuW0> NX3CSldNOC9{L{SgbC=> MVzzeIlufWyjdHXzJGdNWC1zIIPlZ5JmfGmxbjDjc5Rz\WG2ZXSge4l1cCCLQl3Y MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh|Mk[zNUc,OjV6M{K2N|E9N2F-
PBMC NHr2RlZHfW6ldHnvckBCe3OjeR?= M1r4b|UxyqEQvF2= M332[VI1yqCqwrC= MmTSbY5pcWKrdIOgeIhmKGmwY4LlZZNm\CC|ZXPy[ZRqd25ib3[gWG5HKGmwZIXj[YQh[nlidHjlJGRRTQ>? M3LFN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OE[2NFc6Lz5{NUi2OlA4QTxxYU6=
H295R  NGrpRoVHfW6ldHnvckBCe3OjeR?= NELGdGQyOMLizszN NFnPRWg1QMLiaB?= NIfmW2RqdmO{ZXHz[ZMhe3Sncn;p[EBu\XSjYn;sbZRmeyCrbjD0bIUh[W6mcn;n[Y4tKG2rbnXyZYxwNSCjbnSg[4x2[2:lb4L0bYNwcWRicHH0bJdigXN? NGi3fm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2PVU2Pid-MkW4Olk2PTZ:L3G+
3T3-L1 preadipocytes MXPGeY5kfGmxbjDBd5NigQ>? NHnlVncyOCEQvF5CpC=> M3LWPFEzKGh? NXnlNGd1cW6mdXPld{BEWkWEIIDoc5NxcG:{eXzheIlwdiCjbnSgR{9GSlEQsjDlfJBz\XO|aX;u M2PPRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUK4NFU5Lz5{NUmyPFA2QDxxYU6=
PCCL3 NEDJSpNHfW6ldHnvckBCe3OjeR?= NF;ndlkyOCEEtV2= M363NlI1KGh? NGnHbFNmdmijbnPld{BFfU:6MjDwdo9ud3SncjD0doFve2O{aYD0bY9vKGGldHn2bZR6yqEkgJu= MmW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkC5OVYoRjJ3OU[wPVU3RC:jPh?=
SCG Mm[0SpVv[3Srb36gRZN{[Xl? NWXpeotMOTByIN88UeKh M2HucGROW09? NWjyRnM1emWmdXPld{B1cGViZYjjbZRi[mmuaYT5JI9nKFOFRzDu[ZVzd26| MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MkGzNkc,OjV7NkKxN|I9N2F-
HEK-293 NW\EepJLTnWwY4Tpc44hSXO|YYm= NHzHSWc{PSEQvF5CpC=> M{PS[GROW09? MkP0bY5lfWOnczDhJINwdnOyaXP1c5V{KOLCnHnuZYN1cX[jdHnvcwKBpSCxZjD0bIUhU3Z{LkGgZ5VzemWwdB?= NGrrbI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NlE{Oid-MkW5OlIyOzJ:L3G+
SCG MVnGeY5kfGmxbjDBd5NigQ>? M3vYNVIxKM7:TdMg NELzTYlFVVOR MVPy[ZZmenOrYnz5JJN2eHC{ZYPz[ZMhUUuYIIfpeIgh[SCLQ{WwJI9nKDJ2LkSg{txO M2r1UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[yNVMzLz5{NUm2NlE{OjxxYU6=
PC-3 NVTDSoxWS2WubDDWbYFjcWyrdImgRZN{[Xl? NHm4W5A1OCEEtV2= M3z5clI1NzR6L{eyJIg> NVjmUHk3TE2VTx?= NW\B[GNr\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJRqdWViZHXw[Y5l\W62bIm= NFjNboI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|g{Pid-Mk[wNlM5OzZ:L3G+
PC-3 M{jwNGZ2dmO2aX;uJGF{e2G7 M{S1VVQxKML3TR?= NXHKfWRUOiCq MX;EUXNQ NGTub5Ft\WGmczD0c{BRWDKDIHHjeIl3[XSrb36= NF3VWI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|g{Pid-Mk[wNlM5OzZ:L3G+
SH-SY5Y MmK3SpVv[3Srb36gRZN{[Xl? NWWxbW1NOzBizszN MoTTN|AhdWmw M3XYdWROW09? NGS1R4h{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUh[WO2aY\heIlwdiCxZjDQT2E> NUnFbFlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlUyOzdpPkK2NFI2OTN5PD;hQi=>
EndoC-βH1 NHXxZZpHfW6ldHnvckBCe3OjeR?= MVy1xsDPxE1? NGXBVlkyKGh? M3v5NYxm[WS|IITvJIEhe3S{b37nJINCVVBiaX7jdoVie2V? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{OEW2Nkc,OjZyMki1OlI9N2F-
EndoC-βH1 NVTnWog{TnWwY4Tpc44hSXO|YYm= MljqOeKh|ryP MV2xJIg> M1Wx[pBwfGWwdHnheIV{KGeudXPvd4UucW6mdXPl[EBqdnO3bHnuJJNm[3KndHnvckBqdiC2aHWgdJJme2WwY3Wgc4Yh\2y3Y3;z[S=> MkDQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMki1OlIoRjJ4MEK4OVYzRC:jPh?=
RBMECs NUjEboV7TnWwY4Tpc44hSXO|YYm= MVy1xsDPxE1? NWPGW3FmOSCq MWfpcohq[mm2czDFUWFRNUmLLXnu[JVk\WRiaX7hZ5RqfmG2aX;uJI9nKFKjcEJCpC=> NVTifoI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFQ3PjNpPkK2NFQ1PjZ|PD;hQi=>
AML-12  NEfyU5JHfW6ldHnvckBCe3OjeR?= NGi1NXgzOCEQvF2= MofGN{Bp M3XZU4lv\HWlZYOgeIhmKGSncHjvd5Bpd3K7bHH0bY9vKG:oIFPSWGMzyqB? Mn;LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEi5PFUoRjJ4MES4PVg2RC:jPh?=
AML-12  NYfmRXZETnWwY4Tpc44hSXO|YYm= M3TtZlIxKM7:TR?= MlvwN{Bp MYP1dE1z\We3bHH0[ZPDqFCpY{HhMOKhWGWyY3usJIFv\MLiR{\wZ:KhdVKQQTDs[ZZmdHN? NWTrUJBJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFg6QDVpPkK2NFQ5QTh3PD;hQi=>
AML-12  NIfTUVdHfW6ldHnvckBCe3OjeR?= NGPLcJEzOCEQvF2= M2DNcVEuQCCq MXHpcoNz\WG|ZYOg[4x2[2:|ZTDwdo9lfWO2aX;u Mnm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEi5PFUoRjJ4MES4PVg2RC:jPh?=
AML-12  NWSzW4xiTnWwY4Tpc44hSXO|YYm= MlrlNlAh|ryP M4f6NFMhcA>? M3PVSpVxemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ibHX2[Yx{KGG2IGTodk01OTFiYX7kJHNmei12OUO= NUTKdllDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFg6QDVpPkK2NFQ5QTh3PD;hQi=>
Caco-2  M{HH[mZ2dmO2aX;uJGF{e2G7 M3rKbFAvOS9zL{GwJO69VQ>? NFS0W5YzPCCq NIjYR3BqdmO{ZXHz[ZMhVVKSMjDwdo91\WmwIHzleoVt MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OUGwNkc,OjZyNEmxNFI9N2F-
Caco-2  M4HCUmZ2dmO2aX;uJGF{e2G7 MVGwMlEwOS9zMDFOwG0> NHnHN5QzOMLibXnu MV3pcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClQV3QJIxmfmWucx?= MkL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEmxNFIoRjJ4MES5NVAzRC:jPh?=
bovine oocytes M3nyNWZ2dmO2aX;uJGF{e2G7 M2rFU|ExOMLizszN M1fCRVEzyqCq NGjWZ4pqdmirYnn0d{B1cGViZX\m[YN1KG:oIF7QVGEh[W6mL3;yJG5RWENidH:gd5RqdXWuYYTlJJJme3WvcITpc44hd2ZibXXpc5Nqew>? NYTtXWRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVE3OTFpPkK2NFUyPjFzPD;hQi=>
BeWo  MUfGeY5kfGmxbjDBd5NigQ>? NIXJOZEzPeLCid88US=> NX\TbZJyOjRxNEivO|IhcA>? NFHPXoFt\WGmczD0c{BidiCrbnPy[YF{\SCrbjD0bIUh\XiycnXzd4lwdiCxZjDveIhmeiCodYPpc44hdWG{a3Xydy=> NYrq[45PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVM2PDlpPkK2NFU{PTR7PD;hQi=>
Spinal cords  M4Dt[2Z2dmO2aX;uJGF{e2G7 NHTZdG4yyqEQvF2= M4n3UVMxKG2rbh?= MXHzeIlufWyjdHXzJINCVVBibHX2[Yx{ NYrvSIR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlY6OjZpPkK2NVI3QTJ4PD;hQi=>
MDCK  M{n4U2Z2dmO2aX;uJGF{e2G7 NIOxXFgyOCEEtV2= M{TaRVI1KGh? MX\EUXNQ M{HZXIlvcGmkaYTzJJRp\SCrbnPy[YF{\WRiZYjwdoV{e2mxbjDv[kBHViClYYXz[YQh[nliVFfGMe6zOQ>? NF63TJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKwNlM2Oid-Mk[yNFI{PTJ:L3G+
MDCK  NESzPXVHfW6ldHnvckBCe3OjeR?= M3SyfFExKML3TR?= M3XYNFI1KGh? MkPkSG1UVw>? MoPLeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhXEeILd8yNUBidmRiQ2THSuKh NUnXR2cxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFI{PTJpPkK2NlAzOzV{PD;hQi=>
RPMI 8226 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXKwMVExOCEQvF2= NXrOclU3PzMkgJno MoDZbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NF6xRpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOwOlYzPCd-Mk[zNFY3OjR:L3G+
H929 MmK3R4VtdCCYaXHibYxqfHliQYPzZZk> MmHPNE0yODBizszN MmnWO|LjiImq NIjZ[XZqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> M4r5[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{C2OlI1Lz5{NkOwOlYzPDxxYU6=
U266 M1joXmNmdGxiVnnhZoltcXS7IFHzd4F6 MnLFNE0yODBizszN M1XnfVcz6oDLaB?= Mn;vbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NUi3VnZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zNFY3OjRpPkK2N|A3PjJ2PD;hQi=>
OPM-2 Mof0R4VtdCCYaXHibYxqfHliQYPzZZk> MmLYNE0yODBizszN MmfIO|LjiImq M3PreIlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNyNk[yOEc,OjZ|ME[2NlQ9N2F-
INA-6 NIHEZWVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MofZNE0yODBizszN M33qcVcz6oDLaB?= NF;Bem1qdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> M1rjOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{C2OlI1Lz5{NkOwOlYzPDxxYU6=
RBMECs  MVTGeY5kfGmxbjDBd5NigQ>? NGjhblY2yqEQvF2= M{fVOVHDqGh? M1fBWIJtd2OtczD0bIUhWmGlMTDpcoFkfGm4YYTpc44hcW6mdXPl[EBjgSCHTVHQMWlK NHPtWGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1PFA{QSd-Mk[zOVgxOzl:L3G+
Mo-DCs M2\KcGZ2dmO2aX;uJGF{e2G7 MmLSOVAh|ryP Ml;lNlTjiImq M2rhepBzd22xdHXzJGlNNTJ|IIDyc4R2[3Srb36gbY4hfGinIIP1dIVzdmG2YX70JI9nKHq7bX;zZY4he3SrbYXsZZRm\CCPbz3ER5PDqA>? NEW1fHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSxNlk1QCd-Mk[0NVI6PDh:L3G+
HEK293 MnToSpVv[3Srb36gRZN{[Xl? MmC0NVAh|ryP Moq2OkBp NV3Jb3V2cW6lcnXhd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCxdnXy[ZhxemW|c3XkJGtNUEx|IHH0JHM1OzN? M3fyS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEO1OFk5Lz5{NkSzOVQ6QDxxYU6=
ASK NWTzN41{TnWwY4Tpc44h[XO|YYm= NGnJdWkyKGi{ NIDBbI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES5OlQyLz5{OES5OlQyRC:jPh?=
Vero E6 M1S1[GFvfGm4aYLhcEBie3OjeR?= M1z1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nk[zOVM6Lz5zN{[2N|U{QTxxYU6=
epithelial cells NGroe4RHfW6ldHnvckBie3OjeR?= NVPB[nVnOSC3TR?= NFrLflM1NCB4LDDhcoQhQCCmYYnz M4DNXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O|g6Lz5zOUm2Olc5QTxxYU6=
HepG2 (DPX-2) NVK2OZpvTnWwY4Tpc44h[XO|YYm= NGP2ZVIzPCCqcoO= MoHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7Nk[wOFMoRjJyOU[2NFQ{RC:jPh?=
HepG2 M3LaUGZ2dmO2aX;uJIF{e2G7 NWnRNIg3OjRiaILz MkLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7Nk[wOFMoRjJyOU[2NFQ{RC:jPh?=
HepG2 (DPX-2) NFHJXFJHfW6ldHnvckBie3OjeR?= NXP3bFdPOjRiaILz NWTXeJNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5OlYxPDNpPkKwPVY3ODR|PD;hQi=>
HEK293T NXz2Z|I2TnWwY4Tpc44h[XO|YYm= M4TPXVExKHWP MnjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OEezNlUoRjJ2M{i3N|I2RC:jPh?=
HEK293 MmD6SpVv[3Srb36gZZN{[Xl? M2rNWlExKHWP MYWxOkBpenN? NFLWXHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSzOVUyOid-Mk[0N|U2OTJ:L3G+
MCF7 MoXwR5l1d3SxeHnjbZR6KGG|c3H5 NH;B[|E1QCCqcoO= MkX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{i2PVIoRjJ6OEO4OlkzRC:jPh?=
HEK293 M17IUmZ2dmO2aX;uJIF{e2G7 M{TRdVMxKG2rboO= MnHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xO|YoRjNyMEC2NVc3RC:jPh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
Storage powder
in solvent
別名 Coleonol
Smiles CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

cAMPシグナル伝達経路

Tags: Colforsin (Forskolin)を買う | Colforsin (Forskolin) ic50 | Colforsin (Forskolin)供給者 | Colforsin (Forskolin)を購入する | Colforsin (Forskolin)費用 | Colforsin (Forskolin)生産者 | オーダーColforsin (Forskolin) | Colforsin (Forskolin)化学構造 | Colforsin (Forskolin)分子量 | Colforsin (Forskolin)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID